{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:33:06Z","timestamp":1793215986373,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s42000-025-00635-5","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:42:21Z","timestamp":1740001341000},"page":"291-293","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["GLP-1RAs in patients with psoriasis"],"prefix":"10.1007","volume":"24","author":[{"given":"Ioanna A.","family":"Paschou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Sali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-1376","authenticated-orcid":false,"given":"Stavroula A.","family":"Paschou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Psaltopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Electra","family":"Nicolaidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Stratigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"issue":"6","key":"635_CR1","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K (2019) Psoriasis pathogenesis and treatment. Int J Mol Sci 20(6):1475. https:\/\/doi.org\/10.3390\/ijms20061475","journal-title":"Int J Mol Sci"},{"issue":"1","key":"635_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X, Chen Y, Cui L, Shi Y, Guo C (2022) Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis 13(1):81. https:\/\/doi.org\/10.1038\/s41419-022-04523-3. Springer Nature","journal-title":"Cell Death Dis"},{"issue":"4","key":"635_CR3","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87(4):1409\u20131439. https:\/\/doi.org\/10.1152\/physrev.00034.2006","journal-title":"Physiol Rev"},{"key":"635_CR4","doi-asserted-by":"publisher","unstructured":"Wang JY, Wang QW, Yang XY, Yang W, Li DR, Jin JY, Zhang HC, Zhang XF (2023) GLP\u2013\u20091 receptor agonists for the treatment of obesity: role as a promising approach. Front Endocrinol 14. 1085799 Frontiers Media S.A. https:\/\/doi.org\/10.3389\/fendo.2023.1085799.","DOI":"10.3389\/fendo.2023.1085799"},{"issue":"2","key":"635_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jaad.2017.10.050","volume":"78","author":"MT Wan","year":"2018","unstructured":"Wan MT, Shin DB, Hubbard RA, Noe MH, Mehta NN, Gelfand JM (2018) Psoriasis and the risk of diabetes: a prospective population-based cohort study. J Am Acad Dermatol 78(2):315\u2013322e1. https:\/\/doi.org\/10.1016\/j.jaad.2017.10.050","journal-title":"J Am Acad Dermatol"},{"key":"635_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","volume":"150","author":"X Xu","year":"2019","unstructured":"Xu X, Lin L, Chen P, Yu Y, Chen S, Chen X, Shao Z (2019) Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. Diabetes Res Clin Pract 150:167\u2013173. https:\/\/doi.org\/10.1016\/j.diabres.2019.03.002","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"635_CR7","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","volume":"54","author":"AE Hogan","year":"2011","unstructured":"Hogan AE, Tobin AM, Ahern T, Corrigan MA, Gaoatswe G, Jackson R, O\u2019Reilly V, Lynch L, Doherty DG, Moynagh PN, Kirby B, O\u2019Connell J, O\u2019Shea D (2011) Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia 54(11):2745\u20132754. https:\/\/doi.org\/10.1007\/s00125-011-2232-3","journal-title":"Diabetologia"},{"issue":"2","key":"635_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/exd.12081","volume":"22","author":"A Faurschou","year":"2013","unstructured":"Faurschou A, Pedersen J, Gyldenl\u00f8ve M, Poulsen SS, Holst JJ, Thyssen JP, Zachariae C, Vilsb\u00f8ll T, Skov L, Knop FK (2013) Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol 22(2):150\u2013152. https:\/\/doi.org\/10.1111\/exd.12081","journal-title":"Exp Dermatol"},{"issue":"1","key":"635_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.diabet.2011.11.004","volume":"38","author":"M Buysschaert","year":"2012","unstructured":"Buysschaert M, Tennstedt D, Preumont V (2012) Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metabolism 38(1):86\u201388. https:\/\/doi.org\/10.1016\/j.diabet.2011.11.004","journal-title":"Diabetes Metabolism"},{"issue":"11","key":"635_CR10","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","volume":"27","author":"T Ahern","year":"2013","unstructured":"Ahern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B, O\u2019Shea D (2013) Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol 27(11):1440\u20131443. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04609.x","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"635_CR11","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.mehy.2011.09.011","volume":"77","author":"A Faurschou","year":"2011","unstructured":"Faurschou A, Zachariae C, Skov L, Vilsb\u00f8ll T, Knop FK (2011) Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism? Med Hypotheses 77(6):1098\u20131101. https:\/\/doi.org\/10.1016\/j.mehy.2011.09.011","journal-title":"Med Hypotheses"},{"issue":"3","key":"635_CR12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.coi.2008.03.018","volume":"20","author":"JL Matsuda","year":"2008","unstructured":"Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L (2008) CD1d-restricted iNKT cells, the Swiss-Army knife of the immune system. Curr Opin Immunol 20(3):358\u2013368. https:\/\/doi.org\/10.1016\/j.coi.2008.03.018","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"635_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/bjd.12886","volume":"171","author":"M Buysschaert","year":"2014","unstructured":"Buysschaert M, Baeck M, Preumont V, Marot L, Hendrickx E, van Belle A, Dumoutier L (2014) Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study. Br J Dermatol 171(1):155\u2013161 Blackwell Publishing Ltd. https:\/\/doi.org\/10.1111\/bjd.12886","journal-title":"Br J Dermatol"},{"key":"635_CR14","doi-asserted-by":"publisher","unstructured":"Cai Y, Shen X, Ding C, Qi C, Li K, Li X, Jala VR, Zhang H ge, Wang T, Zheng J, Yan J (2011) Pivotal Role of Dermal IL-17-Producing \u03b3\u03b4 T Cells in Skin Inflammation. Immunity 35(4):596\u2013610. https:\/\/doi.org\/10.1016\/j.immuni.2011.08.001","DOI":"10.1016\/j.immuni.2011.08.001"},{"issue":"2","key":"635_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/2042018814543483","volume":"5","author":"MR Al-Badri","year":"2014","unstructured":"Al-Badri MR, Azar ST (2014) Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis. Therapeutic Adv Endocrinol Metabolism 5(2):34\u201338. https:\/\/doi.org\/10.1177\/2042018814543483","journal-title":"Therapeutic Adv Endocrinol Metabolism"},{"issue":"1","key":"635_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00592-011-0359-9","volume":"51","author":"A Faurschou","year":"2014","unstructured":"Faurschou A, Knop FK, Thyssen JP, Zachariae C, Skov L, Vilsb\u00f8ll T (2014) Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol 51(1):147\u2013150. https:\/\/doi.org\/10.1007\/s00592-011-0359-9","journal-title":"Acta Diabetol"},{"issue":"11","key":"635_CR17","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s00125-011-2297-z","volume":"54","author":"DJ Drucker","year":"2011","unstructured":"Drucker DJ, Rosen CF (2011) Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology. Diabetologia 54(11):2741\u20132744. https:\/\/doi.org\/10.1007\/s00125-011-2297-z","journal-title":"Diabetologia"},{"issue":"20","key":"635_CR18","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1007\/s00018-010-0396-5","volume":"67","author":"N Marx","year":"2010","unstructured":"Marx N, Burgmaier M, Heinz P, Ostertag M, Hausauer A, Bach H, Durst R, Hombach V, Walcher D (2010) Glucagon-like peptide-1(1\u201337) inhibits chemokine-induced migration of human CD4-positive lymphocytes. Cell Mol Life Sci 67(20):3549\u20133555. https:\/\/doi.org\/10.1007\/s00018-010-0396-5","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"635_CR19","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","volume":"33","author":"L Lin","year":"2022","unstructured":"Lin L, Xu X, Yu Y, Ye H, He X, Chen S, Chen X, Shao Z, Chen P (2022) Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. J Dermatological Treat 33(3):1428\u20131434. https:\/\/doi.org\/10.1080\/09546634.2020.1826392","journal-title":"J Dermatological Treat"},{"issue":"3","key":"635_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/jdv.12629","volume":"29","author":"A Faurschou","year":"2015","unstructured":"Faurschou A, Gyldenl\u00f8ve M, Rohde U, Thyssen JP, Zachariae C, Skov L, Knop FK, Vilsb\u00f8ll T (2015) Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients - a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol 29(3):555\u2013559. https:\/\/doi.org\/10.1111\/jdv.12629","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-025-00635-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-025-00635-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-025-00635-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:22:45Z","timestamp":1755012165000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-025-00635-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["635"],"URL":"https:\/\/doi.org\/10.1007\/s42000-025-00635-5","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}